George Lombardi Represents Generic Manufacturer in OxyContin Patent Infringement Case

Winston & Strawn partner George Lombardi was quoted in the Law360 article, “OxyContin Patents Not Infringed, Drug Cos. Say At Trial,” published September 23, 2013.

In a patent trial that could end Purdue Pharma LP’s monopoly on certain formulations of OxyContin, Impax Laboratories and other drug manufacturers claim that their generic versions of OxyContin do not infringe Purdue’s patents.

Mr. Lombardi, who represents Impax, said that the companies used basic, well-known methods to make the generic painkillers, and not the novel, proprietary methods claimed by Purdue. “The techniques we used are the conventional standard techniques always used in this industry,” he said.

Mr. Lombardi added that Purdue itself does not actually use the complicated methods on which it has patents, and they are also invalid for various reasons, including earlier work that anticipated them and their purported vagueness.